Leveraging Artificial Intelligence for Neoantigen Prediction

Area of Science:

• Oncology
• Immunology
• Bioinformatics

Background:

• Neoantigens, derived from tumor-specific mutations, are crucial targets for cancer immunotherapy.
• Identifying immunogenic neoantigens that elicit anti-tumor immune responses is challenging due to complex interactions.
• Experimental validation of neoantigens is resource-intensive and inefficient.

Purpose of the Study:

• To provide a comprehensive summary of current artificial intelligence (AI) methodologies for neoantigen prediction.
• To focus on AI's capability in modeling peptide-MHC (pMHC) and pMHC-TCR binding.
• To benchmark the performance of antigen presentation predictors for neoantigen immunogenicity scoring.

Main Methods:

• Review and summarization of existing AI methodologies for neoantigen prediction.
• Analysis of AI models focusing on peptide-MHC (pMHC) binding prediction.
• Benchmarking of AI-driven antigen presentation predictors for immunogenicity assessment.

Main Results:

• AI models are increasingly utilized for discovering immunogenic neoantigens, overcoming experimental limitations.
• The study assessed AI's effectiveness in modeling pMHC and pMHC-TCR interactions.
• Benchmarking analysis evaluated the performance of AI predictors in scoring neoantigen immunogenicity.

Conclusions:

• AI methodologies show significant potential for advancing tumor immunotherapy through precise neoantigen prediction.
• Overcoming current limitations in data, algorithms, and validation is essential for clinical translation.
• Future advancements in AI are expected to enhance the precision and utility of neoantigen discovery.